The pharmacist and adverse drug reaction reporting.
During premarketing trials, the number of patients exposed to a drug and the length of exposure to a drug are both limited. After marketing, many thousands, frequently millions, of patients are exposed to the drug over considerably longer periods of time, and adverse drug reactions not previously recognized appear. Because of these factors, postmarketing surveillance is extremely important. Pharmacists can contribute to drug safety and improved patient care by understanding and actively participating in the Food and Drug Administration's Spontaneous Reporting Program.
D004282:Documentation / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D012042:Registries; D014481:United States; D014486:United States Food and Drug Administration